Evaluation of the incidence and nature of adverse events
OtherEvaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
NCT Number: NCT05311007
High-flow nasal oxygen therapy is commonly used in intensive care unit (ICU). Intra-hospital transfer of critical patients is frequent: 1) to perform diagnostic 2) between emergency room or medical wards and ICU. During theses transfers, oxygenation should be continued.
There is high-flow nasal oxygen therapy for transport using an external battery. This mode of operation in transport mode allows about 30-45 min of autonomy.
Intra-hospital transport under high-flow nasal oxygen therapy has been previously described on children.
The objective of this study is to evaluate the occurrence of complications during intra-hospital transports under high-flow nasal oxygen of critical patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hospital Center of DAX, Dax, France
High-flow nasal oxygen therapy is commonly used in intensive care unit (ICU). Intra-hospital transfer of critical patients is frequent: 1) to perform diagnostic 2) between emergency room or medical wards and ICU. During theses transfers, oxygenation should be continued.
There is high-flow nasal oxygen therapy for transport using an external battery. This mode of operation in transport mode allows about 30-45 min of autonomy.
Intra-hospital transport under high-flow nasal oxygen therapy has been previously described on children.
The objective of this study is to evaluate the occurrence of complications during intra-hospital transports under high-flow nasal oxygen of critical patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Nb: Once the patient is included in the study, any intra-hospital transport under high-flow nasal oxygen therapy will be analyzed until discharge from the intensive care unit and at until D28.
Exclusion criteria
Evaluation of the incidence and nature of adverse events during intra-hospital transport of patients undergoing high-flow nasal oxygen therapy provided by intensive care units
Time frame: Up to 28 days
To evaluate the incidence of severe adverse events during intra-hospital transport of patients treated with high-flow nasal oxygen surpervised by an ICU staff.
Severe adverse event is defined by the occurrence of intubation during transport or severe hypoxemia defined as pulse oxygen saturation (SpO2 < 80%) or cardiorespiratory arrest.
Time frame: Up to 28 days
To evaluate the incidence of minor adverse events during intra-hospital transport of patients treated with high-flow nasal oxygen surpervised by an ICU staff.
Minor adverse event is defined by the occurrence of the need to increase the FiO2 or a pull-out of nasal cannulas or the use of an alternative mode of oxygenation (standard oxygen or noninvasive ventilation) or a failure of high-flow nasal oxygenation system (ie battery failure)
Centre Hospitalier Régional d'Orléans
Other
Intrahospital Transport in Patients With High-flow Nasal Oxygenation: Prospective Observational Study.
Acronym: HospiFlow
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04612348
Critical Illness, Disease Attributes
Columbus, Ohio, United States
View Trial DetailsNCT03195127
Chronic Disease, Critical Illness
Baltimore, Maryland, United States
View Trial DetailsNCT07020637
Critical Illness, Disease Attributes
Las Vegas, Nevada, United States
View Trial DetailsNCT07579728
Critical Illness, Disease Attributes
Istanbul, Turkey (Türkiye)
View Trial Details